Amgen Says ERISA Anemia Drug Claims Lack Merit

Law360, New York (December 17, 2009, 4:29 PM ET) -- Amgen Inc. says there is no merit to a consolidated class action accusing it of violating the Employee Retirement Income Security Act by making false statements about sales growth projections for Aranesp and Epogen in light of safety concerns about the billion-dollar anemia drugs.

The Thousand Oaks, Calif.-based biotech company's filing, lodged Wednesday in the U.S. District Court for the Central District of California, attacks the complaint as based on hindsight and argues that the plaintiffs have had more than enough time to state their case....
To view the full article, register now.